Now Australian scientists have published findings suggesting MGMT may also play a significant role in tumour progression.
Previous work by the same group showed that MGMT was expressed at different levels in pituitary tumours, those with low levels being more aggressive. It is those more aggressive tumours that tend to respond to chemotherapy, because MGMT can no longer undo the damage caused by the drug.
The current study looked closely at 19 pituitary tumours, 12 expressing high levels of MGMT, 7 low, showing very different gene expression profiles between the two groups.
Further investigation also revealed very different gene networks, or ‘signaling pathways’. The tumours with high MGMT expression showed activation of genes implicated in chemotherapy resistance. Those with low MGMT expression showed activation of genes involved in DNA damage and repair, as well as genes involved in gene transcription.
These results led to the formulation of a model describing the possible role of MGMT in pituitary tumour progression – and the conclusion that the results may apply to many other cancer types.
Endocrinologist Dr Ann McCormack, now at Sydney’s Garvan Institute of Medical Research, undertook much of this work in collaboration with Associate Professor Roderick Clifton-Bligh as part of her doctoral studies at the Kolling Institute of Medical Research. Microarray analysis and Gene Set Enrichment Analysis were done with Dr Warren Kaplan from Garvan. The findings are described in Pituitary, now online.
“Pituitary tumours display a strong tendency towards ‘senescence’, akin to hibernation, and most do not become aggressive or malignant,” said Dr McCormack.
“In a small number of cases, however, the tumours emerge from their senescent state and become aggressive. It is likely that prolonged DNA damage signaling contributes to this progression.”
“This study told us that loss of MGMT expression may contribute to the progressive accumulation of genetic mutations and cellular proliferation that occurs.”
“We feel these results would be of interest to other cancer researchers. There has been substantial literature regarding MGMT as a biomarker of response to temozolomide, however, this is the first paper to examine the relationship between MGMT and genome-wide gene expression profiles in any tumour type.”
“We believe that as well as being a biomarker of treatment response, MGMT may ultimately serve to reflect tumour biology and act as a prognostic indicator. These are preliminary findings and we now need to validate our results.”
The Garvan Institute of Medical Research was founded in 1963. Initially a research department of St Vincent’s Hospital in Sydney, it is now one of Australia’s largest medical research institutions with over 500 scientists, students and support staff. Garvan’s main research programs are: Cancer, Diabetes & Obesity, Immunology and Inflammation and Neuroscience. Garvan’s mission is to make significant contributions to medical science that will change the directions of science and medicine and have major impacts on human health. The outcome of Garvan’s discoveries is the development of better methods of diagnosis, treatment, and ultimately, prevention of disease.
All media enquiries should be directed to:
Science Communications Manager
M: + 61 434 071 326
P: +61 2 9295 8128
E: a.heather “a” garvan.org.au